Martine van Vugt

Director/Board Member at SCANDION ONCOLOGY A/S

71 year

Health Technology

Consumer Services

Profile

Martine J.
van Vugt is currently an Independent Director at Scandion Oncology A, a Director at Hollandbio, the Chief Strategy Officer & Executive Vice President at Genmab A, an Independent Member-Supervisory Board at TME Pharma NV, and a Member-Supervisory Board at Immagene BV.
Dr. van Vugt holds a doctorate degree from the University of Utrecht and a graduate degree from Wageningen University.

Martine van Vugt active positions

Companies	Position	Start
GENMAB A/S	Corporate Officer/Principal	2023-03-28
TME PHARMA N.V.	Director/Board Member	2021-06-23
SCANDION ONCOLOGY A/S	Director/Board Member	2022-03-31
Immagene BV Immagene BV Pharmaceuticals: MajorHealth Technology Immagene BV is a private biotech company based in the Netherlands that is dedicated to developing next-generation precision immuno-oncology treatments. Immagene is committed to transforming cancer treatment and has a focus on precision medicine. The Dutch company was founded on world-leading research from the Netherlands Cancer Institute and drug R & D expertise from industry veterans. The company was founded by Maarten Ligtenberg, Christian Blank, and Daniel Peeper, with Maarten Ligtenberg serving as the CEO since incorporation.	Director/Board Member	-
Hollandbio	Director/Board Member	-

All active positions of Martine van Vugt

Training of Martine van Vugt

University of Utrecht	Doctorate Degree
Wageningen University	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Martine van Vugt's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
GENMAB A/S	Health Technology
TME PHARMA N.V.	Health Technology
SCANDION ONCOLOGY A/S	Health Technology

Private companies	2
Hollandbio
Immagene BV Immagene BV Pharmaceuticals: MajorHealth Technology Immagene BV is a private biotech company based in the Netherlands that is dedicated to developing next-generation precision immuno-oncology treatments. Immagene is committed to transforming cancer treatment and has a focus on precision medicine. The Dutch company was founded on world-leading research from the Netherlands Cancer Institute and drug R & D expertise from industry veterans. The company was founded by Maarten Ligtenberg, Christian Blank, and Daniel Peeper, with Maarten Ligtenberg serving as the CEO since incorporation.	Health Technology